Home › Therapeutic areas › Ophthalmology
Ophthalmology (23 companies · 21 conditions)
Conditions
Diabetic Macular Edema 6 Wet AMD 6 Dry Eye Disease 5 Geographic Atrophy 5 Inherited Retinal Disease 5 Rare Diabetic Retinopathy 3 Thyroid Eye Disease 3 Non-Arteritic Anterior Ischemic Optic Neuropathy 2 Rare Presbyopia 2 Retinal Vein Occlusion 2 Stargardt Disease 2 Rare Age-Related Macular Degeneration 1 Allergic Conjunctivitis 1 Autosomal Recessive Bestrophinopathy 1 Rare Best Vitelliform Macular Dystrophy 1 Rare Macular Edema 1 Ocular Surface Inflammation 1 Optic Neuritis 1 Retinopathy of Prematurity 1 Rare Uveitis 1 Rare X-linked Retinitis Pigmentosa 1 Rare
Companies
| Ticker | Company | Therapeutic areas | In Ophthalmology | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| FDMT | 4D Molecular Therapeutics | OphthalmologyRespiratory Rare | 3 | Phase 3 | $677M | 5 |
| AKBA | Akebia Therapeutics | HematologyOphthalmology+2 Rare | 1 | Approved | $111M | 10 |
| ALDX | Aldeyra Therapeutics | DermatologyOncology+1 | 3 | NDA Submitted | $38.3M | 5 |
| ANNX | Annexon | HematologyNeurology+2 Rare | 1 | Phase 3 | $796M | 6 |
| BLTE | Belite Bio | MetabolicOphthalmology Rare | 2 | NDA Submitted | $6.21B | 6 |
| BIOA | BioAge Labs | CardiovascularOphthalmology | 1 | Phase 2 | $245M | 2 |
| EYPT | EyePoint | Ophthalmology | 1 | Phase 3 | $31.0M | 2 |
| HROW | Harrow | Ophthalmology Rare | 6 | Approved | $1.01B | 15 |
| KPRX | Kiora Pharmaceuticals | Ophthalmology Rare | 3 | Phase 3 | $6.4M | 4 |
| KOD | Kodiak Sciences | Ophthalmology | 6 | Phase 3 | $6.24B | 8 |
| LENZ | LENZ Therapeutics | Ophthalmology | 1 | Approved | $110M | 1 |
| LCTX | Lineage Cell Therapeutics | MetabolicNeurology+1 Rare | 2 | Phase 2 | $258M | 12 |
| MGTX | MeiraGTx | ImmunologyMetabolic+2 Rare | 3 | Phase 3 | $864M | 16 |
| NBP | NovaBridge Biosciences | OncologyOphthalmology | 1 | Phase 2 | $106M | 7 |
| OCGN | Ocugen | Infectious DiseaseOphthalmology Rare | 7 | Phase 3 | $314M | 12 |
| OCS | Oculis Holding | NeurologyOphthalmology Rare | 3 | Phase 3 | $417M | 5 |
| IRD | Opus Genetics | Ophthalmology Rare | 10 | Approved | $348M | 12 |
| OTLK | Outlook Therapeutics | Ophthalmology | 3 | Approved | $106M | 3 |
| PTN | Palatin Technologies | ImmunologyMetabolic+1 Rare | 1 | Phase 3 | $11.2M | 8 |
| SEPN | Septerna | ImmunologyMetabolic+1 Rare | 1 | Phase 1 | $2.28B | 5 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 1 | Approved | $231M | 27 |
| VRDN | Viridian Therapeutics | ImmunologyOphthalmology | 3 | Approved | $3.24B | 7 |
| ZBIO | Zenas BioPharma | DermatologyImmunology+2 Rare | 1 | NDA Submitted | $1.92B | 11 |
No companies match.